(NASDAQ: ALMS) Alumis's forecast annual revenue growth rate of 163.21% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 32.37%, and it is also forecast to beat the US market's average forecast revenue growth rate of 13.52%.
Alumis's revenue in 2026 is $7,398,000.On average, 12 Wall Street analysts forecast ALMS's revenue for 2026 to be $889,090,657, with the lowest ALMS revenue forecast at $431,278,216, and the highest ALMS revenue forecast at $1,821,153,813. On average, 12 Wall Street analysts forecast ALMS's revenue for 2027 to be $3,212,712,067, with the lowest ALMS revenue forecast at $0, and the highest ALMS revenue forecast at $9,527,080,767.
In 2028, ALMS is forecast to generate $20,641,037,563 in revenue, with the lowest revenue forecast at $10,566,316,301 and the highest revenue forecast at $41,995,263,294.